Eris Lifesciences Moat Analysis: Score & Risks
Eris Lifesciences Ltd.
A first-pass moat teardown of Eris Lifesciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Eris Lifesciences Ltd. scores 5.31 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Operating leverage: The manufacturing facility in Guwahati, Assam currently operating at ≈80% capacity utilisation on a two shift basis is capable of being scaled up to triple shift basis.”
“Domestic Branded Formulations EBITDA margin expanded from 34.5% in FY24 to 36.5% in FY25; an increase of ~200 bps driven by synergies from business integration.”
“further solidified our position with marquee brands such as Basalog and Insugen into our th portfolio making Eris the 5 largest Diabetes franchise in India.”
“Swiss Parenterals now ranks among a select few Indian injectable cos to have received both EU and ANVISA regulatory approvals”
“Kunal, our DBF MR strength is close to 3,700-plus now. More than 560 reps added through the two Biocon deals. That's where we stand right now.”
“the business model would be to look at 3-to-5-year manufacturing contracts for sale in the EU, and these come with higher customer stickiness and lower price sensitivity given that these are injectables.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion